214 related articles for article (PubMed ID: 16291292)
1. The CATIE schizophrenia effectiveness trial.
Delisi LE; Nasrallah HA
Schizophr Res; 2005 Dec; 80(1):v-vi. PubMed ID: 16291292
[No Abstract] [Full Text] [Related]
2. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
3. Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.
Rosenheck R; Lin H
J Nerv Ment Dis; 2014 Jan; 202(1):18-24. PubMed ID: 24375207
[TBL] [Abstract][Full Text] [Related]
4. Interpreting the results of the CATIE study.
Pandiani JA; Banks SM
Psychiatr Serv; 2006 Jan; 57(1):140-1. PubMed ID: 16399981
[No Abstract] [Full Text] [Related]
5. Did CATIE influence antipsychotic use?
Citrome L; Jaffe A; Martello D; Allingham B; Levine J
Psychiatr Serv; 2008 May; 59(5):476. PubMed ID: 18451000
[No Abstract] [Full Text] [Related]
6. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
[TBL] [Abstract][Full Text] [Related]
7. Schizophrenia, VI: Treatments.
Lieberman JA; Stroup TS
Am J Psychiatry; 2003 Oct; 160(10):1748. PubMed ID: 14514482
[No Abstract] [Full Text] [Related]
8. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
[TBL] [Abstract][Full Text] [Related]
9. What CATIE found: results from the schizophrenia trial.
Swartz MS; Stroup TS; McEvoy JP; Davis SM; Rosenheck RA; Keefe RS; Hsiao JK; Lieberman JA
Psychiatr Serv; 2008 May; 59(5):500-6. PubMed ID: 18451005
[TBL] [Abstract][Full Text] [Related]
10. Antiaggressive action of combined risperidone and quetiapine in a patient with schizophrenia.
Bozikas VP; Deseri C; Pitsavas S; Karavatos A
Can J Psychiatry; 2003 Jul; 48(6):426-7. PubMed ID: 12894620
[No Abstract] [Full Text] [Related]
11. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
[TBL] [Abstract][Full Text] [Related]
12. The outpatient use of atypical antipsychotics with Alzheimer's disease.
Farver D
S D Med; 2007 Mar; 60(3):113, 115. PubMed ID: 17455580
[No Abstract] [Full Text] [Related]
13. Interpreting the results of the CATIE study.
Lieberman JA; Hsiao JK
Psychiatr Serv; 2006 Jan; 57(1):139. PubMed ID: 16399980
[No Abstract] [Full Text] [Related]
14. Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
Ramsey TL; Brennan MD
Schizophr Res; 2014 Dec; 160(1-3):73-9. PubMed ID: 25449714
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Swartz MS; Wagner HR; Swanson JW; Stroup TS; McEvoy JP; Reimherr F; Miller DD; McGee M; Khan A; Canive JM; Davis SM; Hsiao JK; Lieberman JA;
Schizophr Res; 2008 Mar; 100(1-3):39-52. PubMed ID: 18191383
[TBL] [Abstract][Full Text] [Related]
16. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics.
Gianfrancesco FD; Rajagopalan K; Sajatovic M; Wang RH
Psychiatry Res; 2006 Nov; 144(2-3):177-89. PubMed ID: 17010448
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic drugs and schizophrenia.
Dettling M; Anghelescu IG
N Engl J Med; 2006 Jan; 354(3):298-300; author reply 298-300. PubMed ID: 16421374
[No Abstract] [Full Text] [Related]
18. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Swartz MS; Perkins DO; Stroup TS; Davis SM; Capuano G; Rosenheck RA; Reimherr F; McGee MF; Keefe RS; McEvoy JP; Hsiao JK; Lieberman JA;
Am J Psychiatry; 2007 Mar; 164(3):428-36. PubMed ID: 17329467
[TBL] [Abstract][Full Text] [Related]
19. Psychopharmacology news.
Silva R
J Child Adolesc Psychopharmacol; 2009 Feb; 19(1):91. PubMed ID: 19232027
[No Abstract] [Full Text] [Related]
20. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.
Faries D; Ascher-Svanum H; Zhu B; Correll C; Kane J
BMC Psychiatry; 2005 May; 5():26. PubMed ID: 15921508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
